Swedbank AB Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swedbank AB increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 160.3% in the third quarter, Holdings Channel reports. The firm owned 53,729 shares of the biopharmaceutical company’s stock after buying an additional 33,090 shares during the period. Swedbank AB’s holdings in Alnylam Pharmaceuticals were worth $14,777,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Huntington National Bank increased its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter worth $42,000. Finally, Friedenthal Financial purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $51,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALNY. Piper Sandler reissued an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:ALNY opened at $253.35 on Wednesday. The company has a market cap of $32.68 billion, a price-to-earnings ratio of -96.70 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm’s 50-day simple moving average is $272.74 and its 200-day simple moving average is $239.37. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.